Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > Why do this deal?

<< Previous

Bullboard Posts

Next >>

Comment by mike49on May 02, 2020 8:46pm

265 Views

Post# 30980251

RE:Why do this deal?

Why does the deal seem strange?
Not being facetious but odds are same dudes who vended in original properties are same guys now talking joint venture.
polyester cowboys and no different than the small auctioneers who sell the same junk to each other every sale hoping for a rube to finally take it off their hands.
The next scam for these cats will be to try and access gov money to clean up their mess.
Watch plx get joys' junk and consider it a win.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide